JP2024503635A - 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 - Google Patents

線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Download PDF

Info

Publication number
JP2024503635A
JP2024503635A JP2023541262A JP2023541262A JP2024503635A JP 2024503635 A JP2024503635 A JP 2024503635A JP 2023541262 A JP2023541262 A JP 2023541262A JP 2023541262 A JP2023541262 A JP 2023541262A JP 2024503635 A JP2024503635 A JP 2024503635A
Authority
JP
Japan
Prior art keywords
cys
pro
group
compound
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503635A5 (https=
Inventor
オステルカンプ，フランク
ハーセ，クリスチャン
シュナイダー，エベラール
プロクシュ，ヨナス
ズボロウスキー，ディルク
パシュケ，マティアス
スマーリング，クリスチャン
ライニキー，ウルリッチ
Original Assignee
３ベー ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ３ベー ファーマシューティカルズ ゲーエムベーハー filed Critical ３ベー ファーマシューティカルズ ゲーエムベーハー
Publication of JP2024503635A publication Critical patent/JP2024503635A/ja
Publication of JP2024503635A5 publication Critical patent/JP2024503635A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023541262A 2021-01-07 2022-01-07 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 Pending JP2024503635A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21150562.3A EP4050018A1 (en) 2021-01-07 2021-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof
EPEP21150562 2021-01-07
PCT/EP2022/050294 WO2022148851A1 (en) 2021-01-07 2022-01-07 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (2)

Publication Number Publication Date
JP2024503635A true JP2024503635A (ja) 2024-01-26
JP2024503635A5 JP2024503635A5 (https=) 2025-01-16

Family

ID=74215696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541262A Pending JP2024503635A (ja) 2021-01-07 2022-01-07 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Country Status (9)

Country Link
US (1) US20240115745A1 (https=)
EP (2) EP4050018A1 (https=)
JP (1) JP2024503635A (https=)
KR (1) KR20230129260A (https=)
CN (1) CN116940586A (https=)
AU (1) AU2022205776A1 (https=)
CA (1) CA3206481A1 (https=)
IL (1) IL303926A (https=)
WO (1) WO2022148851A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
US20250270238A1 (en) * 2022-05-20 2025-08-28 The Governors Of The University Of Alberta A new bifunctional linchpin that reacts selectively with cysteine residues to invoke cyclization while concurrently introducing a dotaga moiety for radiometal chelation
PE20251640A1 (es) * 2022-09-07 2025-06-24 3B Pharmaceuticals Gmbh Ligandos de antigeno de membrana especifica de la prostata (psma) y uso de los mismos
IL322552A (en) * 2023-02-10 2025-10-01 Chengdu New Radiomedicine Tech Co Ltd Polypeptide compound and its use
WO2024198838A1 (zh) * 2023-03-27 2024-10-03 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
KR20260026051A (ko) * 2023-06-14 2026-02-25 마리아나 온콜로지 인크. Dll3 표적화 펩티드 및 이의 구성체
CN121712788A (zh) * 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
CN121712787A (zh) * 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
WO2025082283A1 (zh) * 2023-10-16 2025-04-24 四川科伦博泰生物医药股份有限公司 环肽结构的配体化合物及其核素标记物、药物组合物及应用
GB202318958D0 (en) * 2023-12-12 2024-01-24 King S College London Compound
WO2025163556A1 (en) 2024-02-01 2025-08-07 Novartis Ag Methods for treating cancer
WO2025179168A1 (en) * 2024-02-22 2025-08-28 Mariana Oncology Inc. Synthesis of dll3-binding peptides
WO2026017046A1 (zh) * 2024-07-19 2026-01-22 晶核生物医药科技(南京)有限公司 一种环多肽、其制备方法和应用
WO2026021314A1 (zh) * 2024-07-22 2026-01-29 山东威智知科药业有限公司 Fap化合物及其用途
CN120590466A (zh) * 2025-08-06 2025-09-05 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种靶向成纤维细胞活化蛋白的化合物及其应用
CN121045338A (zh) * 2025-11-05 2025-12-02 原子高科股份有限公司 一种靶向caix的环肽及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042282A2 (en) * 2004-10-12 2006-04-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2019083990A2 (en) * 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)
WO2021005131A1 (en) * 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
ATE357509T1 (de) 1997-09-29 2007-04-15 Point Therapeutics Inc Stimulierung von hämatopoietischen zellen im vitro
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
US7399869B2 (en) 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
CA2806021C (en) 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3763726A1 (en) * 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042282A2 (en) * 2004-10-12 2006-04-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
JP2018515066A (ja) * 2015-03-17 2018-06-14 バイオンテック アーゲー がんの診断及び処置のための組成物及び方法
WO2019083990A2 (en) * 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)
WO2021005131A1 (en) * 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof

Also Published As

Publication number Publication date
WO2022148851A1 (en) 2022-07-14
CN116940586A (zh) 2023-10-24
AU2022205776A1 (en) 2023-07-27
EP4274836A1 (en) 2023-11-15
CA3206481A1 (en) 2022-07-14
EP4050018A1 (en) 2022-08-31
KR20230129260A (ko) 2023-09-07
IL303926A (en) 2023-08-01
US20240115745A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2024503635A (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2024503637A (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP7783396B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022410422B2 (en) Carbonic anhydrase ix ligands
CN118591549A (zh) 碳酸酐酶ix配位体
EP4610269A1 (en) Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260331